Back

Scenario 1 - Adverse events of new lipid lowering drugs.

26 August 2018 (11:05 - 11:30)
Organised by:
Congress Presentation Part of: Meet the Experts - Safety first: avoiding adverse events with new cardiovascular drugs Cardiovascular Pharmacotherapy ESC Premium Access ESC Congress 2018

About the speaker

Photo
Doctor Trygve Sundby Hall

Oslo University Hospital Ulleval, Oslo (Norway)

5 More presentations in this session

Presentation thumbnail
Safety first: avoiding adverse events with new cardiovascular drugs - Panel
Presentation thumbnail
Introduction - Safety first: avoiding adverse events with new cardiovascular drugs
Doctor M. Alonso Garcia (London, GB)
Slides Video
Presentation thumbnail
Scenario 2 - Neprilysin inhibitors in heart failure: safety and adverse events
Assistant Professor M. Kaluzna-Oleksy (Poznan, PL)
Slides
Presentation thumbnail
Scenario 3 - Long-term safety of new anti-diabetic drugs.
Professor A. Niessner (Vienna, AT)
Slides Video
Presentation thumbnail
Safety first: avoiding adverse events with new cardiovascular drugs - Take Home Message.
Professor J. Tamargo (Madrid, ES)
Slides Video

Access the full session

Session thumbnail
Meet the Experts - Safety first: avoiding adverse events with new cardiovascular drugs

The Event

Event poster

ESC Congress 2018

26 August 2018 11:05 CET
You may be interested in
thumbnail
Webinar
Post-ACS management of dyslipidaemia: tips and tricks from real world experiences
16 December 2020
thumbnail
Congress Presentation
Targeting RNA for treatment of dyslipidaemias.
26 August 2022
thumbnail
Webinar
Update of the 2019 ESC Guidelines on Management of Dyslipidaemia: new recommendations and their impact on clinical practice
25 November 2025
thumbnail
Webinar
New trial evidence in the field of lipid management
19 April 2024

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources